Europäische Kommission genehmigt Anwendung von Janssens Stelara® (Ustekinumab) zur Behandlung von mittelschwerer bis schwerer aktiver Colitis Ulcerosa in der EU



  1. 1.
    European Commission (2019) Product information – Stelara. Zugegriffen: September 2019Google Scholar
  2. 2.
    Toussirot E (2012) The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 11:159–168CrossRefGoogle Scholar
  3. 3.
    Ng SC et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390:2769–2778CrossRefGoogle Scholar
  4. 4.
    Crohn’s, Foundation C ‘Living with Ulcerative Colitis’ leaflet. Zugegriffen: August 2019
  5. 5.
    Crohn's, Colitis UK What is Ulcerative Colitis? Zugegriffen: August 2019
  6. 6.
    Lopez-Sanroman A et al (2017) Perceived emotional and psychological impact of ulcerative colitis on outpatients in Spain: UC-LIFE survey. Dig Dis Sci 62:207–216CrossRefGoogle Scholar
  7. 7.
    Rubin D et al (2010) The impact of ulcerative colitis on patients’ lives compared to other chronic diseases:A patient survey. Dig Dis Sci 55:1044–1052CrossRefGoogle Scholar
  8. 8.
    Devlen J et al (2014) The burden of inflammatory bowel disease: A patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis 20:545–552CrossRefGoogle Scholar
  9. 9.
    Lonnfors S et al (2014) IBD and health-related quality of life – Discovering the true impact. J Crohns Colitis 8:1281–1286CrossRefGoogle Scholar
  10. 10.
    Sandborn WJ, et al. Abstract OP37: Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI. ECCO 2019.Google Scholar
  11. 11.
    Sands B, et al. Safety and efficacy of ustekinumab induction therapy in patients with moderate to severe ulcerative colitis: results from the Phase 3 UNIFI study [abstract]. Presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, 5–10 October 2018; Philadelphia, Pennsylvania.Google Scholar
  12. 12.
    European Medicines Agency (2019) Stelara opinion from Committee for Medicinal Products for Human Use (CHMP) 25 July. Zugegriffen: August 2019Google Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2019

Personalised recommendations